Ledgewood Wealth Advisors LLC Decreases Stock Position in Johnson & Johnson $JNJ

Ledgewood Wealth Advisors LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 9,483 shares of the company’s stock after selling 149 shares during the period. Johnson & Johnson comprises 0.9% of Ledgewood Wealth Advisors LLC’s portfolio, making the stock its 24th largest position. Ledgewood Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,448,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Elios Financial Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after acquiring an additional 66 shares in the last quarter. Atlantic Family Wealth LLC raised its holdings in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after acquiring an additional 67 shares in the last quarter. MBA Advisors LLC raised its holdings in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares in the last quarter. Sovereign Financial Group Inc. raised its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc raised its holdings in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after acquiring an additional 69 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Weiss Ratings restated a “hold (c+)” rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Bank of America raised their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday. Finally, Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $187.47.

Johnson & Johnson Stock Up 1.4%

JNJ stock opened at $188.51 on Friday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.78. The firm’s 50-day simple moving average is $176.18 and its 200 day simple moving average is $162.83. The stock has a market cap of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.